Abstract
Chronic cortisol hypersecretion causes central obesity, hypertension, insulin resistance, dyslipidemia, protrombotic state, manifestations which form a metabolic syndrome in all patients with Cushing's syndrome. These associated abnormalities determine an increased cardiovascular risk not only during the active phase of the disease but also long after the “biomedical remission”. Clinical management of these patients should be particularly careful in identifyin global cardiovascular risk. Considering that remission from hypercortisolism is often difficult to achieve care and controlof all cardiovascular risk factors should be one of the primary goals during the follow up of these patients. Extending theindications of the recent consensus on Cushing's syndrome, we suggest to carry out an OGTT to avoid underestimation of diabetes mellitus, an echocardiography and Doppler ultrasonography of the epiaortic vessels in all patients at diagnosisand during follow-up.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos G, Fava GA, Findling J, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M. Diagnosis and complications of Cushing's Syndrome: A Consensus Statement. J Clin Endocrinal Metab 2003;88:5593–5602.
Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G. Persistence of increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure. J Clin Endocrinal Metab 1999;84:2664–2672.
Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: An epidemiological approach. Clin Endocrinal 1994;23:479–48.
Andrews RC, Walker BR. Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci 1999;96:513–523.
Danese RD, Aron DC. Cushing's syndrome and hypertension. Endocrinal Metab Clin of North America 1994;23:299–223.
Giraldi FP, Moro M, Cavagnini F. Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of Endocrinology. Gender-related differences in the presentation and course of Cushing's disease. J Clin Endocr Metab 2003;88:1554–1558.
Mancini T, Kola B, Concettoni C, Boscaro M, Mantero F, Arnaldi G. Hypertension in patients with Cushing's syndrome: Evidence for gender difference in 11β hydroxysteroid dehydrogenase type 2 activity. The Endocrine Society 85nd Annual Meeting, Philadelphia, P2-606, 2003;454 (Abstract).
Magiakou MA, Mastrokaros G, Olfield EA, Gomez MT, Doppman JL, Cutler GBJ, Nieman LK. Chrousos GPCushing's syndrome in children and adolescents: Presentation, diagnosis and therapy. New England J Med 1994;331:629–636.
Biglieri EG, Kater CE, Mantero F. Adrenocortical forms of human hypertension. In: Laragh, Brenner (Eds), Hypertension, 2nd edn. Raven Press, 1995:2145.
Sala C, Ambrosi B, Morganti A. Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with Cushing's disease. J Clin Endocrinol Metab 2001;86:1957–1961.
Mantero F, Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol 1992;43:409–413.
Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, Rosei EA, Mantero F, Fallo F. Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol 2003;41:2275–2279.
Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A. Cardiovascular risk factors and common carotid artery calibre and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003;88:2527–2533.
Andrews RC, Walker BR. Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci 1999;96:513–523.
Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002;87:3662–3666.
Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A, Camaschella C. Hyperhomocysteinemia in patients with Cushing's Syndrome. J Clin Endocrinol Metab 2004;89:3745–3751.
Kirilov G, Tomova A, Dakovska L, Kumanov Ph, Shinkov A, Alexandrov AS. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's Syndrome. Eur J Endocrinol 2004;49:549–553.
Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004;61:768–767.
Chalmers J. WHO-ISH Hypertension Guidelines Committee. World Health Organization—International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151–185.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by grant MIUR-PRIN 2004 prot. 2004058593 to Marco Boscaro
Rights and permissions
About this article
Cite this article
Arnaldi, G., Mancini, T., Polenta, B. et al. Cardiovascular Risk In Cushing's Syndrome. Pituitary 7, 253–256 (2004). https://doi.org/10.1007/s11102-005-1172-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-005-1172-7